456 related articles for article (PubMed ID: 27182616)
1. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
[TBL] [Abstract][Full Text] [Related]
2. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
4. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
5. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
7. Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.
Kamal El-Din MA; Farhan MS; El Shiha RI; El-Kaffas RM; Mousa SM
Paediatr Drugs; 2014 Aug; 16(4):337-41. PubMed ID: 24797541
[TBL] [Abstract][Full Text] [Related]
8. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
9. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
10. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
11. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
16. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
17. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
18. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
